Previous 10 | Next 10 |
JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $6.25 per share and accom...
Triterras (TRIT) -17%.SCYNEXIS (SCYX) -18% after initiates equity raise of $50M.ADDvantage Technologies Group (AEY) -13% on Q4 earnings release.Uxin (UXIN) -11% on FQ2 earnings release.Anchiano Therapeutics (ANCN) -11%.Sonnet BioTherapeutics Holdings (SONN)&...
Gainers: [[SCPS]] +27.7%. [[EOLS]] +23.2%. [[GTAT]] +21.8%. [[MGNX]] +15.7%. [[SELB]] +10.3%.Losers: [[SCYX]] -15.8%. [[QTT]] -9.2%. [[APEN]] -6.8%. [[TRITW]] -6.7%. [[ETM]] -4.3%. For further details see: SCPS, EOLS, SCYX and QTT among after-hours movers
SCYNEXIS (SCYX) has commenced a $50M underwritten public offering of shares and warrants, including pre-funded warrants.Number of shares, price are yet to be determined. For further details see: SCYNEXIS initiates equity raise of $50M
JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock i...
Approval granted by h ealth authority for t he intravenous (IV) formulation of ibrexafungerp to enter Phase 1 ; dosing in healthy volunteers to start in the first quarter of 2021 New interim analysis of the data from the Phase 3 st...
Under priority review status, the FDA has accepted SCYNEXIS's ([[SCYX]] +1.6%) marketing approval seeking approval for ibrexafungerp for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infections.Agency's action date is set at June 1, 2021. Additionally, the FDA ha...
6-month Priority Review granted for ibrexafungerp with PDUFA t arget a ction d ate set for June 1, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting for the applicati...
JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler ...
SCYNEXIS (SCYX): Q3 GAAP EPS of -$0.28.Cash and cash equivalents of $29.5M.Press Release For further details see: SCYNEXIS reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...